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Abstract
The alphaherpesvirus that causes chicken pox and shingles, varicella-zoster virus
(VZV), infects skin fibroblasts and keratinocytes. These cells are typically
quiescent and it is known that VZV manipulates their intracellular environment
to activate MAPK signaling cascades, cell cycle regulators, and many
transcription factors for its replication. We hypothesized that inhibition of cell
kinases would prevent VZV replication and also elucidate which pathways are
most important. We evaluated 80 kinase inhibitors for cytotoxicity and antiproliferative effects on human foreskin fibroblasts, and then determined their
antiviral efficacy against VZV-ORF9-Luc strain. Ten well-tolerated, potent
kinase inhibitors whose targets are critical mediators of VZV infection were
identified. Receptor tyrosine kinases (EGFRK, NGFRK and PDGFRK) were
pivotal for VZV replication and 3 potent compounds inhibited these targets
(Tyrphostin AG1478, AG-879, Tyrphostin 9). Their common downstream
substrates were also found to be necessary for VZV replication: protein kinase A
(PKA, H-89•2HCl) and protein kinase C (PKC, GF 109203X and PKC-412).
Other potent compounds blocked the activity of calmodulin-dependent protein
kinase (CaMKII, KN-62) and glycogen synthase kinase 3-beta (GSK-3β,
Indirubin-3’-monooxime and Kenpaullone). We also identified one compound
with previously known antiviral activity, the cyclin-dependent kinase inhibitor
Roscovitine. Thus VZV infection causes changes in the intracellular
environment that expose antiviral targets in multiple pathways.
This abstract was presented at the 27th International Conference on Antiviral
Research, May 12-16, 2014, Raleigh, NC.
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Executive Summary
Varicella-zoster virus (VZV) is a human-restricted herpesvirus that
causes chickenpox (varicella) and shingles (zoster). Primary viral infection
results in chickenpox, a generally mild disease that is typically contracted during
childhood and presents with scattered, itchy skin pustules. Following initial
infection, VZV, like other viruses in the herpes family, becomes dormant in
nerve cells. The virus can reactivate spontaneously to cause shingles, a disease
characterized by a localized, painful skin rash. The most common complication
associated with shingles is postherpetic neuralgia (PHN)the persistence of
debilitating pain for months or years even after the infection and rash have
resolved.
The Centers for Disease Control and Prevention (CDC) estimate that 3.5
million cases of varicella occur every year and that by age 40, the virus has
infected 99.5% of people born in the U.S. Approximately one in three people
will develop shingles in their lifetime, leading to one million cases each year in
this country. The incidence of zoster and PHN increases with age, and with
millions of ‘baby boomers’ set to join the group at the highest risk, the
development of more effective antiviral drugs is crucial.
Problems associated with the vaccines and current antiviral medications
necessitate new methods of treatment. The varicella vaccines, Varivax and
Zostavax, consist of a live virus that cannot be given to people who are
immunocompromised, although they have a very high risk for zoster. The
shingles vaccine is only approved for individuals over 50 years old, and zoster
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occurs even in about half of people who are immunized. Acyclovir, the primary
medication used to treat zoster, is effective only within 48 hours after the onset of
symptoms, and this drug is ten times less potent against VZV than other
herpesviruses. Although the vaccines have prevented many cases of chicken
pox and shingles, and acyclovir has helped some people recover from the
infections, there is a compelling need for new treatments for this virus.
VZV, like all viruses, cannot replicate outside of a living host—it lacks
the machinery necessary to carry out its own reproductive processes and must
hijack the infrastructure of host cells. In so doing, it activates host kinases that
send signals throughout the cell to facilitate viral replication mechanisms.
Kinases are proteins that transfer high-energy phosphate groups to specific
substrates, a reaction that typically ‘turns on’ its target. These kinases are
typically linked into cascades that transduce signals from a cell’s exterior to
intracellular effectors, which in the case of VZV infection are factors necessary
for replication of viral DNA and the production of viral proteins. VZV is known
to activate specific kinases during its life cycle to gain access to these mediators,
but there are inevitably more that have yet to be identified.
The goal of this project, therefore, was to elucidate additional kinases
important in VZV replication by inhibiting their activity with compounds that
block their ability to transfer phosphate groups. This way, we could assess the
relative importance of specific targets in the viral life cycle. We hoped that by
identifying the most essential kinases we could expand our knowledge of VZVhost interactions and identify potential targets of antiviral drugs.
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To do this, we purchased eighty kinase-inhibiting compounds with welldefined targets. The first step in the process was to assess the safety of each
compound in lab-grown human fibroblasts, a type of skin cell. This was crucial
because compounds that killed cells they were meant to treat would likely cause
significant side effects in patients. We compared drug-treated cells with nontreated cells to determine the effect of each inhibitor on cell viability. We then
eliminated compounds that were toxic since they would be of little value in a
medical setting.
Next, we studied the effect of non-toxic compounds on cell division.
Cellular division, of course, is an essential process of living organisms in which
kinases play a particularly important role. To make sure that inhibiting specific
proteins did not prevent normal cellular proliferation, we measured the amount of
cell division that took place in drug-treated fibroblasts after 48 hours. Drugs that
prevented an increase in the number of cells relative to the beginning of the
experiment were removed from the study because they, too, would likely be
disadvantageous in a clinical setting.
Seventy of the original eighty inhibitors were nontoxic in these tests. We
subsequently determined the antiviral efficacy of the remaining compounds in
VZV-infected skin cells. We found a wide range of antiviral activity exhibited
by the inhibitors and narrowed our focus to the sixteen most potent compounds.
For each of the most effective compounds, we calculated a Selectivity Index (SI),
which measures a compound’s ability to prevent viral processes without
deleteriously affecting the host. This step identified ten compounds whose
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targets represent important mediators in VZV replication. Excitingly, a number
of these proteins were implicated by more than one compound, which confirms
the importance of their role in virus replication.
The cellular targets implicated by our findings are constituents of
multiple signaling pathways, a number of which were previously unidentified as
mediators of VZV replication. Moreover, the kinases we identified as important
antiviral targets act at multiple levels of these pathways and are capable of
eliciting a variety of responses that are crucial in the viral life cycle. Given the
hierarchical nature of these cascade proteins, it is possible that combining
inhibitors to block multiple kinases at the same time would result in synergistic
antiviral effects. Drug therapy targeting host cell functions is particularly
promising because viruses are much less likely to develop resistance to these
drugs than current antiviral medications. It is our hope that the identification of
these antiviral targets will ultimately lead to novel clinical treatments of
chickenpox and shingles.
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Introduction
Varicella-zoster virus (VZV) is an alphaherpesvirus that causes both
chicken pox (varicella) and shingles (herpes zoster). The virus is highly
contagious and is spread primarily through aerosols and contact with infected
skin lesions. Varicella is a common illness that is typically acquired during
childhood. The Centers for Disease Control and Prevention (CDC) estimate that
approximately 3.5 million new cases of chicken pox develop each year.
Varicella has an incubation period of 10-21 days and presents with systemic,
itchy skin lesions and fever and, although the disease is generally mild, can cause
severe complications or even death, particularly in people who are older or
immunocompromised (Balfour, 1988; De La Blanchardiere et al., 2000).
Varicella also poses a threat to pregnant women, developing fetuses, and
newborns, since perinatal transmission may cause severe neurological defects
and organ damage (Gnann, 2002).
The virus establishes latency in dorsal root ganglia following initial
varicella infection and can reactivate spontaneously years or decades later as
zoster. Anyone with prior exposure to live virus is at risk for developing
shingles. This is of particular concern because the CDC estimates that 99.5% of
American-born citizens over the age of 40 have had varicella. The mechanisms
and causes of reactivation are incompletely understood but once VZV is
acquired, the threat of a reemerging infection remains for life. Reactivation of
dormant virus can be the result of physical or psychological stress, the loss of
cell-mediated immunity caused by immunosuppression or senescence, as well as
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a number of other genetic and demographic factors (Thomas & Hall, 2004).
Zoster is characterized by a painful, vesicular rash in localized regions of the
body, typically along a dermatome enervated by the ganglion where latency was
established. Complications of zoster include facial paralysis, pneumonia,
encephalitis, and vision loss (Gnann, 2002; Volpi, 2007), although such serious
problems are rare. The most common complication associated with zoster,
however, is postherpetic neuralgia (PHN), a debilitating condition characterized
by pain in the affected region that can persist for months or years even after the
resolution of infection and skin lesions (Tenser, 2001). The incidence of herpes
zoster in the United States is rising, with total cases increasing across all age
groups between 1993 and 2006 (Leung et al., 2011; Yih et al., 2005). The CDC
approximates the incidence of zoster in the US at 4 cases per 1000 persons
annually and 10 cases per 1000 persons over the age of 60, with an estimated 1
million total cases occurring each year (2014). The CDC now estimates that 1 in
3 people will develop shingles in their lifetime.
Vaccines against varicella and zoster have proven effective in reducing
annual cases of VZV infection and associated complications but come with their
own problems. The varicella vaccine, Varivax (Merck), has substantially
reduced the incidence of varicella-associated mortality and morbidity in the US
since its use began in 1995 (Davis et al., 2004; Nguyen et al., 2005). However,
breakthrough cases occur in 15-20% of inoculated individuals (Schmid &
Jumaan, 2010; Ampofo et al., 2002). Furthermore, because Varivax is a live
virus, it is not 100% effective at preventing establishment of latent virus and

11
protecting against reactivation to zoster (Hambleton et al., 2008.) and live
vaccines are not safe for immunocompromised patients. The varicella vaccine
may also be contributing to the recently observed rise in cases of herpes zoster by
lowering the extent of exogenous VZV exposure, which may act as a natural
“booster shot” for previously infected individuals (Wagenpfeil et al., 2004).
Without this boost, cell-mediated immunity diminishes continuously with age
and the risk of reactivation increases across the lifespan. Data implicating the
role of the varicella vaccine in this theory, however, have thus far proven
inconclusive (Reynolds et al., 2008).
The zoster vaccine, Zostavax (Merck), is approximately 50% effective at
preventing shingles and 90% effective against postherpetic neuralgia (Sanford &
Keating, 2010), but the vaccine is only approved for people 50 and older. While
that covers most individuals at the highest risk, a large portion of susceptible
hosts are not eligible to receive the vaccine. In addition, Zostavax is expensive
compared to other vaccines and is not covered by all insurance plans, further
limiting access to it (Harvard Family Health Guide). The zoster vaccine, like the
varicella vaccine, also uses a live, attenuated virus and is not appropriate for
inoculation of immunocompromised individuals who are at highest risk for
reactivation.
A number of antiviral medications are currently used for clinical
treatment of varicella and zoster but like the vaccines, each presents their own
challenges. The most commonly used drugs, acyclovir, famciclovir, and
valaciclovir, are modified to their active forms by the viral enzyme thymidine
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kinase. The active forms of these compounds are nucleoside analogues that
incorporate into viral DNA and prevent replication. Acyclovir, while useful in
treating VZV infection, is ten times less effective against VZV than the related
herpes simplex viruses, and, because it is poorly absorbed, must be administered
five times a day (Arvin, 1996). Famciclovir and valaciclovir are better absorbed
than acyclovir but are not approved for use in treating zoster in
immunocompromised patients (Arvin, 1996). Furthermore, treatment with these
drugs must be started within 96 hours after appearance of skin lesions to decrease
the severity of illness. These antivirals also do not prevent or remove latent virus
and therefore offer no protection against viral reactivation (Arvin, 1996).
These drugs have the advantage of selectively targeting VZV-infected
cells but also promote the emergence of drug resistance. The thymidine kinase
gene is not essential for viral replication, so prolonged use of these nucleoside
analogues can select for thymidine kinase-negative mutants that are unresponsive
to acyclovir (Arvin, 1996). Such acyclovir-resistant strains have indeed been
well documented in immunocompromised patients (Linnemann et al., 1990;
Léger et al., 2001; Pahwa et al., 1988). Acyclovir-resistant infections can be
treated with Foscarnet, a drug that is highly toxic and can cause significant
metabolic side effects (Coen & Schaffer, 2003), making it a less than desirable
alternative.
The existence of these vaccines and antiviral medications, while
important in minimizing the impact of varicella and zoster, has reduced the
urgency for the development of safer and more effective drugs. The problems
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associated with the virus-centered method of current treatment programs
necessitate a new approach. To this end, a new paradigm has emerged in
antiviral research-- the therapeutic targeting of host enzymes that are important
mediators of viral replication. Viruses are, by nature, obligate intracellular
parasites and depend on the action of many host signal transduction pathways to
carry out processes like gene expression, replication, and packaging (Münter et
al., 2006). Blocking access to host proteins involved in cellular signaling
pathways has the potential to disrupt normal virus-host interactions that are
essential for the viral life cycle. This approach also has the advantage of
presenting a more substantial barrier to the development of drug resistance than
current treatments. Viruses rely on host signaling machinery because they lack
genes for the proteins that carry out replication processes. It is unlikely that
mutations in the VZV genome would give rise to resistance to these treatments
because the virus is totally dependent on the activity of those specific proteins
and has no way of subverting the signaling pathways when they are blocked.
Given the importance of these virus-host interactions, the primary goal of
this project was to identify cellular signaling pathways involved in VZV
infection. Previous studies have shown that VZV affects the activity of host
protein kinases involved in phosphorylation cascades (Zapata et al., 2007; Liu et
al., 2012; Liu & Cohen, 2013) that regulate transcription, cell survival, and cell
cycle progression among other processes. With this information in mind, we
hypothesized that we could elucidate specific pathways and mediators VZV uses
for replication by evaluating a kinase inhibitor panel in cultured human skin
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cells. Similar approaches have been used in other areas of infectious disease
research and are now accepted methods for studying pathogen-host pathway
interactions (Hussain et al., 2010; Goswami et al., 2012).
The goal of this project was to identify compounds that would be well
tolerated by host cells but also effective at preventing viral replication. Such
compounds would point to a cellular target whose activity was more important to
VZV than the host. This difference in selectivity could be exploited in the
clinical treatment of varicella and zoster.
To perform the study, we purchased a kinase inhibitor library containing
80 different compounds with well-defined molecular targets. The first objective
was to demonstrate which compounds could be safely administered to the skin
cells without causing cell death or inhibiting growth. The second objective was
to test whether treatment with the kinase inhibitors resulted in a reduction of
VZV infection. The final objective was to further assess the in vitro therapeutic
efficacy of the most potent drugs identified in the second step by quantifying
their selectivity for interrupting viral replication over host processes. Classifying
the inhibitors in this way would allow us to discern the most important protein
targets on which to focus future drug development efforts.
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Materials and Methods
Cell and Virus Culture. Human foreskin fibroblasts (HFFs) (CCD-1137Sk;
American Type Culture Collection, Manassas, VA) and MeWo cells, an
immortalized human melanoma line, (a gift of Dr. Charles Grose, University of
Iowa) were grown in Eagle minimum essential medium with Earle’s balanced
salts and L-glutamine (HyClone Laboratories, Logan, UT) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (Benchmark FBS; Gemini Bio
Products, West Sacramento, CA), amphotericin-B (250µg/mL), penicillinstreptomycin (5000 IU/mL), and non-essential amino acid solution (all
Mediatech, Manassas, VA) at 37oC under 5% CO2. HFFs, a primary cell line,
were grown for up to 20 passages. VZV-BAC-Luc (Zhang et al., 2007) was
derived from the Parental Oka strain, a wild type clinical isolate from Japan
(Accession number: AB097933). Dr. Hua Zhu (University of Medicine and
Dentistry of New Jersey) provided a master stock of VZV-BAC-Luc (passage
10). VZV-BAC-Luc was stored at -80°C and grown on HFFs for up to 10
passages.

Drug Handling and Preparation. A panel of 80 kinase inhibitors, the ScreenWell® Kinase Inhibitor Library (Product Number: BML-2832-0100), was
purchased from Enzo Life Sciences, Inc. (Farmingdale, NY). Drugs were
supplied as 100 µL of 10 mM stock dissolved in DMSO in deep, 96-well plates.
We prepared 30 µL of 2 mM (MTT and Dose Response) and 10 mM (Neutral
Red) replica plate aliquots for indicated assays. The library and aliquots were
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stored at -80oC and protected from light until use. Drugs in all experiments were
thawed at room temperature before dilution to final concentration in complete
tissue culture medium (TCM) at 37oC.

Neutral Red (NR) Cytotoxicity Assay. The NR assay was performed in clear,
96-well plates with 5x103 HFF cells/well. The cells were cultured for 24 h until
reaching confluence, and then the medium was removed and replaced with 200
µL of medium containing the test drug. Drugs were evaluated at 12.5, 25, 50,
and 100 µM. Four drugs were tested on each plate with inhibitors tested in
triplicate and controls in replicates of six. The outside wells were filled with 200
µL of TCM during cell growth periods but received no cells or treatment (Figure
1). Following addition of drug, each plate was covered with an adhesive plastic
sheet and incubated for 48 h. The drugs were removed before the NR stain
solution was added [93% TCM, 1% non-essential amino acids, 5% FBS, 1%
Neutral Red (Sigma-Aldrich, St. Louis, MO) dissolved in Dulbecco’s Phosphate
Buffered Saline with Ca2+ and Mg2+ (Mediatech Inc., Manassas, VA), filtered to
clarify]. Neutral Red is absorbed by pinocytosis and accumulates in lysosomes;
the amount of dye absorbed by the culture is proportional to the number of living
cells. 250 µL of NR stain solution was added to each well and incubated for 2 h.
Neutral Red solution was removed and cells were fixed with 250 µL of 0.5%
formaldehyde (Fisher Scientific, Fair Lawn, NJ) in DPBS for 10 min at room
temperature. The fixative solution was removed and replaced with 100 µL of
desorb solution [50% ethanol (Ultra Pure LLC, Darien, CT), 1% glacial acetic
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acidd (Fisher Scientific, Fair Lawn, NJ) in distilled water]. Plates were then
wrapped in aluminum foil and gently agitated on an orbital shaker for 25 min at
room temperature. Following desorption of the stain, the amount of NR present
in each well was meas
measured
ured by a spectrophotometer with absorbance at 540 nm.
All absorbance measurements were compared to a diluent (DMSO) negative
control that showed no toxic effects and to a posit
positive
ive control, staurosporine,
which kills cells by apoptosis. Absorbance values substantially
ly lower than the
th
diluent were considered indicative of cytotoxicity.

Figure 1.. Plate layout of Neutral Red Assay
Assay. Stauro wells indicate staurosporine-treated
treated positive controls.
Diluent wells indicate DMSO
DMSO-treated negative controls.

MTT Cellular Proliferation Assay. The MTT (3-(4,5-dimethylthiazol
dimethylthiazol-2-yl)2,5-diphenyltetrazolium
diphenyltetrazolium bromide
bromide)) Cellular Proliferation Assay is a rapid screen
to assess the effect of all 80 inhibitors oon
n cell growth and division. The assay
was performed in clear, 96
96-well plates on sub-confluent HFFs
(1.67x103cells/well) that were cultured for 24 h. A Time 0 replicate plate for
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each experiment was prepared for an initial measurement of cell number before
drug was added. Each data point of the Time 0 plate was the average of 6
replicate wells. Following initial incubation, seeding media was removed and
replaced with 200 µL of drug solution. Drugs were tested at 1.5, 3, 6, and 12 µM
in triplicate wells. The outside wells were filled with 200 µL of TCM during cell
growth periods but received no cells or treatment (Fig. 2). Following addition of
drug, each plate was covered with an adhesive plastic sheet and incubated for 48
h. Twenty µL of 5 mg/mL MTT dissolved in PBS was added on top of existing
drug solution and incubated for 3.5 h. MTT is a yellow tetrazolium salt that is
absorbed and reduced to a purple formazan in metabolically active, dividing cells
by dehydrogenase and reductase enzymes. Solutions were then removed and
replaced with 150 µL of DMSO, a solvent of MTT. Plates were wrapped in
aluminum foil and gently agitated on an orbital shaker for 15 min at room
temperature. Once solubilized by the addition of DMSO, the amount of
formazan was measured by a spectrophotometer. Absorbance was measured at
590 nm. The same quantification procedure was followed for 0 and 48 hour
plates. Non-dividing cells do not reduce the solution and thus produce less
formazan. Therefore, the absorbance is proportional to the amount of
proliferative cells present. Absorbance measurements of treated wells were then
compared to controls of 1 mM phosphonoformate (PFA), a compound that does
not inhibit cell division, and blank wells receiving only TCM and MTT solution
and ultimately assessed against absorbance measured in the Time 0 samples.
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Figure 2.. Plate layout of MTT Assay. Wells marked as Blank contained no cells and were treated only
with MTT as a negative control
control. PFA wells received phosphonoformate as a positive control.

Response Assay. The Dose-Response
Response Assay was performed in black, 96Dose-Response
well plates with 2.5x103 HFF cells/well infected with VZV-ORF9
ORF9-Luc as a rapid
screening process to assess antiviral efficacy of non
non-toxic
toxic and non-inhibitory
non
drugs. The strain of virus used in this assay encodes the gene for firefly
luciferase, an enzyme that cleaves the D
D-luciferin substrate-- a reaction that
releases photons that can be measured with bioluminescence imaging. Upon the
addition of D-luciferin,
luciferin, cells that express the luciferase enzyme emit photons in
proportion to the amount of VZV infection. Photon emission measurements
measu
were used to calculate VZV yield. Cells were plated with TCM and grown
overnight for 24 h. TCM was then removed and cells were infected with 100 µL
of TCM containing sonicated, cell-free VZV-ORF9-Luc showing more than 80%
cytopathic effect (CPE) at a 1:25 ratio of infected to uninfected cells and
adsorbed for two hours at 37
37°C. 100 µL of drug solutions were added on top of
viral media for final concentrations of 1.5, 3, 6, and 12 µM in triplicate. Controls

20
of DMSO (diluent
(diluent) at the same concentration
tion as the highest drug dose and 1 mM
PFA were used in replicates of six
six. Drug treatments were compared to the
diluent control in order to calculate percent VZV yield, with the average of
diluent-treated
treated values taken as 100%. The outside wells were filled
fill with 200 µL
of TCM during cell growth periods but received no cells or treatment (Fig. 3).
Following addition of drug, each plate was covered with an adhesive plastic sheet
and incubated for 48 h. VZV yield was then determined by bioluminescence
imaging
ng using the IVIS
IVIS-50® instrument (Caliper Life Sciences/Xenogen,
Hopkinton, MA) and expressed as total flux (photons/sec
(photons/sec/steradian/cm
/steradian/cm2).

Figure 3.. Plate layout of Dose Response Assay
Assay. All wells received media containing cell-free
cell
VZV. Wells
with PFA received phospho
phosphonoformate
oformate as a positive control. Wells with Diluent indicate DMSO-treated
DMSO
negative controls.

EC50 Assay. The EC50 is the concentration of a drug that reduces viral yield by
half. To determine the EC50, it was necessary to lower the concentrations at
which the compounds were surveyed in the Dose Response Assay, as many of
them reduced VZV yield more than 50% at 1.5 µM. Drug concentrations used in
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this assay were two
two-fold dilutions ranging from 0.094-24 µM
M (Fig. 4). The goal
of this concentration expansion was to find a range of 00-100%
100% viral yield that
would allow the interpolation the EC50 from a resulting dose response curve.
VZV yield from drug
drug-treated
treated wells was compared to the yield from untreated
wells,
ells, with the average measurement from the untreated wells taken as 100%
viral yield. The procedure of the assay was identical to that of the Dose
Response assay with the exception that VZV
VZV-ORF9-Luc
Luc was used at a 1:20 ratio
of infected to uninfected cell
cells. Results were plotted as the percent virus yield
versus the drug concentration on a Log10 scale, and then analyzed by non-linear
non
regression to estimate the EC50 value. A plate containing DMSO with the same
dilutions as the test plates accompanied each eexperiment
xperiment as a control (there was
no effect on virus yield).

Figure 4.. Plate layout of EC50 Assay. All wells received media containing cell-free
free VZV. This layout was
also used for the DMSO control plates.

Statistical Analysis. Statistical analyses were performed using Microsoft Excel
2011 and GraphPad Prism 5.02 for Windows and 5.0b for Macintosh (GraphPad
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Software, San Diego, CA, www.graphpad.com). Data points represent mean
values and all error bars represent the standard deviation. EC50 concentrations
were determined by interpolation of non-linear regression curves and the
Selectivity Index (SI) was calculated by dividing the cytotoxic concentration by
the EC50 concentration. For drugs that were nontoxic at all levels of the NR
Assay, 100 µM was applied as the cytotoxic concentration in calculating SI.
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Results
As an obligate intracellular parasite, VZV relies on intimate interactions with its
host cell. Limiting the viral life cycle by disrupting these relationships presents a
unique set of challenges. Unlike the previously mentioned antiviral drugs that
target VZV-specific processes, the compounds in this study target host proteins.
Inhibition of host kinases has the potential to shut down crucial pathways and
cause a number of deleterious alterations of the intracellular environment, even
in uninfected cells. The primary objective in identifying cellular targets of VZV,
therefore, was to determine which compounds could be safely administered
within a range of concentrations that were both non-toxic and non-inhibitory to
quiescent, uninfected cells. For this reason, the NR Cytotoxicity and MTT
Cellular Proliferation assays were performed in human foreskin fibroblasts
(HFFs), which are primary cultured cells that serve as a good host for VZV
infection. The antiviral efficacy of nontoxic inhibitors was then assessed by the
Dose Response Assay using VZV-ORF9-Luc infected HFFs. The most potent
drugs were selected for further analysis by the EC50 Assay to determine their
efficacy as inhibitors of viral replication and to calculate a Selectivity Index, an
industry-standard quantification of the concentration range between which a
compound is antiviral and adequately tolerated by the cell.
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Neutral Red Cytotoxicty Assay. The NR Assay was performed in confluent
HFFs to assess cytotoxicity of all 80 compounds. For values that were not
judged to be cytotoxic but were less than the diluent, we suspect that some of the
reduction in cell number was due to anti-proliferative effects of the drugs at high
doses that prevented HFFs from growing and completely filling the wells.
Furthermore, because the ultimate goal was to test as many compounds as
possible for antiviral effects, we allowed some absorbance values considerably
lower than the diluent value to pass the NR Assay. To qualify for further study,
compounds had to be suitably nontoxic at 12.5 µM or higher. Compounds failing
either this test or the MTT Assay were not used in the antiviral assays.
Compounds that serve to illustrate the application of selection criteria of the NR
Assay are shown (Fig. 5). Staurosporine was cytotoxic at all concentrations and
thus was disqualified from antiviral assays. Wortmannin was toxic from 25-100
µM but was determined to be safe enough at 12.5 µM to warrant further study.
Both AG-490 and Tyrphostin 9 passed at all concentrations. Most compounds in
the library showed minimal cytotoxic effects and qualified for additional analysis
(Table 1).
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Effect on Cell Viability of Selected Compounds
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Figure 5. NR Assay for cytotoxicity. Absorbance of cells treated with indicated compounds at four
concentrations (100, 50, 25, and 12.5 µM). Values are the average ± standard deviation of triplicate
samples. Diluent represents numerical average of all control samples. Experimental measurements were
compared to the diluent to determine degree of cell viability.

MTT Cellular Proliferation Assay. The MTT Assay was performed in subconfluent HFFs in order to assess the level at which each drug inhibited cellular
division. Cells were used at one-third the density of the NR Assay to give the
cells space to divide. All 48-hour measurements were compared to an
accompanying Time 0 plate to assess the degree of proliferation. Absorbance
values below or equivalent to the Time 0 readings were interpreted as antiproliferative. Compounds found to be anti-proliferative at 1.5 µM were
disqualified. Examples illustrating the process used in assessing drugs by the
MTT Assay are shown (Fig 6). Wortmannin was cytostatic at all concentrations
tested. Although it passed the NR Assay at 12.5 µM, these results disqualified
Wortmannin from antiviral assays. AG-490 and Tyrphostin 9 passed at all
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concentrations. Most drugs that passed the NR Assay were also found to be noninhibitory (Table 1).
Effect on Cellular Proliferation of Selected Compounds
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Figure 6. MTT Assay for cell proliferation. Absorbance of cells treated with indicated compounds at
four concentrations (12, 3, 6, and 1.5 µM). Values are the average ± standard deviation of triplicate
samples. Time 0 represents numerical average of all Time 0 absorbance values. Experimental
measurements were compared to Time 0 to determine extent of cell proliferation.

Dose Response Assay. Ten inhibitors that were determined to be cytotoxic or
cytostatic at low levels by the NR and MTT Assays, respectively, were removed
from the panel and the remaining 70 drugs were evaluated for their antiviral
potential. Drugs that reduced VZV yield to less than 20% at 12 µM were
considered highly potent and were further analyzed by the EC50 Assay. Drugs
that did not meet this cutoff were disqualified. Illustrative examples of antiviral
analysis are shown (Fig 7). AG-490 reduced viral yield to only ~50% at 12 µM,
well above the required 20% needed for further study. Tyrphostin 9 was a highly
effective antiviral compound, nearly eliminating VZV infection at 12 µM.
Indeed, the lowest concentration of Tryphostin 9 tested, 1.5 µM, reduced VZV
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yield below 50%, indicating that the range of concentrations in this assay was too
high for this potent compound. Most of the drugs displayed an antiviral effect,
with seventeen compounds demonstrating considerable potency (Table 1).

Reduction of VZV by Selected Compounds
150

VZV Yield (%)

AG-490
Tyrphostin 9

100

50

0
1

10

Concentration (µM)

Figure 7. Percent VZV yield in cells treated with indicated compounds at four concentrations (1.5, 3, 6, and
12 µM). Photons/second of each compound at each concentration was divided by the average
photons/second of diluent replicates on the plate on which it was tested to determine percent VZV yield

EC50 Assay. The EC50 Assay was performed on the 17 qualifying compounds to
determine the concentration at which the inhibitors reduced viral yield by 50%
for use in SI calculations. The results for Tyrphostin 25 were inconclusive and
could not be fitted to a sigmoidal curve, so its EC50 and SI were not calculated.
For both Tyrphostin AG1478 and PKC-412, the EC50 appeared to be outside the
bottom range of the assay, but an approximate EC50 was still interpolated from
the regression fit of each drug. An example of a dose response regression curve
used to interpolate the EC50 is shown (Fig. 8). An EC50 was reliably interpolated
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Table 1. Results of NR, MTT, and Dose Response Assays. All cytotoxicity and growth arrest numbers
represent the lowest concentration, in µM, in which the respective effect was observed. Percent VZV yield
represents data collected at 12 µM. * SP 600125 was not removed because it was previously shown to have
antiviral effects in VZV (Zapata et al., 2007).

Compound Name
Tyrphostin 9
RG-1462
H-89  2HCl
GF 109203X
Roscovitine
PKC-412
Tyrphostin AG1478
Tyrphostin 25
Terreic Acid
Indirubin-3’-monooxime
KN-93
Kenpaullone
N9-isopropyl-olomoucine
KN-62
AG-879
Triciribine
Tyrphostin 23
U-0126
AG-494
Lavendustin A
BML-259
*
SP 600125
Tyrphostin 47
PP1
H-7  2HCl
ML-9  HCl
HA-1077  2HCl
ML-7  HCl
GW 5074
SB-202190
Tyrphostin 51
LY 294002
Tyrphostin AG1288
5,6-dichloro-1-β-D-ribofuranosylbenzimidazole
SB-203580
Olomoucine
H-9  HCl
ZM 336372
SU 4312
Tyrphostin 1

Cytotoxicity

Growth
Arrest

% VZV
Yield

>100
25
50
50
50
100
100
25
25
50
25
100
50
25
100
>100
>100
>100
>100
100
50
12.5
>100
100
50
50
>100
50
>100
100
100
>100
>100
100
100
>100
50
100
100
>100

>12
>12
12
>12
>12
6
12
>12
12
12
>12
3
>12
>12
>12
12
>12
>12
12
>12
12
6
>12
>12
>12
3
12
>12
>12
12
>12
12
6
6
>12
>12
>12
6
12
>12

0.9
2.0
2.6
2.8
5.3
5.3
6.0
7.0
7.6
8.5
8.9
11.6
12.7
12.8
14.0
16.9
18.0
21.0
21.0
21.0
21.0
21.7
23.0
23.1
24.0
25.3
26.0
26.4
27.1
29.2
31.0
31.0
31.0
31.0
32.0
32.0
33.0
34.6
37.9
39.0
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Compound Name
HA-1004  2HCl
PD-98059
Y-27632  2HCl
LFM-A13
Piceatannol
2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'dimethanol dimethyl ether
Indirubin
ZM 449829
2-Aminopurine
AG-126
AG-1296
Apigenin
SC-514
Daidzein
2-Hydroxy-5-(2,5-dihydroxybenzylamino)
benzoic acid
SU 1498
AG-490
Genistein
H-8
Tyrphostin 46
Palmitoyl-DL-carnitine
Rapamycin
Quercetin  2H2O
Iso-olomoucine
Tyrphostin AG1295
BML-257
AG-825
Hypericin
Hydroxy-2-naphthalenylmethylphosphonic acid
AG-370
Wortmannin
D-erythro-Sphingosine
PP2
Rottlerin
BAY 11-7082
BML-265
5-Iodotubericidin
Erbstatin analog
Staurosporine
Ro 31-8220 mesylate

Cytotoxicity

Growth
Arrest

% VZV
Yield

>100
>100
50
>100
50
25

12
>12
12
12
6
3

41.3
42.0
42.6
42.7
42.9
43.0

>100
100
>100
>100
50
100
>100
>100
100

3
>12
>12
>12
>12
12
12
3
12

43.3
43.5
44.0
48.0
49.0
50.0
50.4
51.0
51.0

25
>100
>100
100
>100
100
25
>100
>100
>100
>100
100
50
>100
>100
25
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5

>12
>12
3
>12
>12
>12
12
12
12
12
12
>12
12
6
>12
<1.5
6
6
6
6
6
3
3
<1.5
1.5

51.9
52.0
53.0
53.7
54.0
54.5
54.5
59.3
59.8
62.0
64.0
65.0
65.0
72.9
112.0
-----------
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from most regression curves (Table 2).

Tyrphostin 9 EC50 Determination

VZV Yield (%)

150
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0
0.01

0.1
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Concentration (µM)
Figure 8. Non-linear regression of Tyrphostin 9 (R2 = .9144). Concentrations are in two-fold dilutions
from 0.09375-24 µM. EC50 = 1.3 µM, as determined by interpolation by GraphPad software.

Selectivity Indices. The Selectivity Index (SI) is a comprehensive ranking of the
safety and efficacy of a drug. An SI value of 10 or greater was considered the
cutoff for determining the best drugs. Of the sixteen compounds for which an
EC50 concentration was determined, ten had an SI greater than 10 and are
candidates for future study (Table 2). These ten highly effective compounds
implicate a number of important pathways and enzymes necessary for VZV
replication. Amongst them are three growth factor receptor kinase inhibitors
(Tyrphostin AG1478, Tyrphostin 9, and AG-879) and a number of their
downstream effectors, including two protein kinase C inhibitors (PKC-412 and
GF 109203X), two glycogen synthase kinase 3 beta (GSK-3β) inhibitors
(Kenpaullone and Indirubin-3’-monooxime), a calmodulin-dependent protein
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kinase (CaMKII) inhibitor (KN-62), a cyclin-dependent kinase (CDK) inhibitor
(Roscovitine), and a protein kinase A inhibitor (H89  2HCl).
Table 2. Results of EC50 Assays and SI values. Applied cytotoxicity represents the value used in
calculating SI. Regression curves could not be reliably fit for drugs marked * so their SI values may
actually be larger than indicated. Drugs marked ** were nontoxic at 100 µM so their SI values may actually
be larger than shown.

Drug

Applied
Cytotoxicity (µM)

EC50 (µM)

SI

Tyrphostin AG1478*

100

0.22

454.4

PKC-412*

100

0.45

222.2

Tyrphostin 9**

100

1.3

76.9

Kenpaullone

100

2.9

34.5

KN-62

25

0.86

29.1

GF 109203X

50

1.9

26.3

Indirubin-3’-monooxime

50

2.9

17.2

Roscovitine

50

2.9

17.2

H-89  2HCl

50

3.1

16.1

AG-879

100

9.7

10.3

N9-isopropylolomoucine
Terreic Acid

50

5.6

8.9

25

3.1

8.1

Triciribine**

100

13.0

7.7

Tyrphostin 23**

100

13.2

7.6

KN-93

25

4.3

5.8

RG-1462

25

4.6

5.4
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Discussion
In this study we identified several important cellular kinases utilized by
VZV during viral replication by inhibiting their activity with specific
compounds. Understanding the roles of the identified host proteins in the viral
life cycle will expand our knowledge of VZV infection and has the potential to
lead to novel approaches to antiviral therapy.
The results of the Neutral Red Assay identified a number of inhibitors
that were too toxic in non-infected cells to warrant further study. The drugs used
in this study were capable of causing deleterious consequences in host tissue ―
they directly targeted mediators of cell survival, growth, differentiation, division,
and gene expression pathways that are crucial elements of living systems. Some
of the drugs may prevent virus replication but at the cost of severely inhibiting
host cellular processes or cell death. This would, of course, limit the potential
value of such a drug in treating a non-malignant illness like varicella or zoster.
The concentrations used in these experiments (0-100 µM) were much higher than
would be administered in a clinical setting, where it is difficult to achieve a
concentration greater than 10 µM in vivo. Compounds were required to be nontoxic at 12.5 µM because this concentration was closest to the real-world value.
We were confident that host cells would tolerate compounds that were non-toxic
at 12.5 µM or higher. This proved to be a reasonable cutoff, as it left us with 71
of the original 80 compounds that were safe for use in cultured cells. The
eliminated compounds were simply too harsh and complications associated with
their use could likely outweigh any potential antiviral activity.
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Results of the cellular proliferation assay indicated that the majority of
compounds tested did not severely inhibit cell division. A non-toxic compound
could still limit the rate of important metabolic processes crucial for normal cell
activity without causing cell death. Like cytotoxic compounds, inhibitors that
cause such problems would not be useful in the clinical treatment of VZV. The
MTT Assay was performed to measure the effect of the inhibitors on cell growth
and division. The cutoff used for these experiments was 1.5 µM but, for a
number of reasons, it was not as important or strictly applied as the toxicity
cutoff. For one, these compounds are designed to be anti-proliferative and,
indeed, some of them are currently being studied as anti-cancer therapies
(Giamas et al., 2010; Hidalgo & Rowinsky, 2000; Y. Zhang et al., 2008).
Furthermore, most cells in vivo are not dividing, and, important for our purposes,
VZV grows well in quiescent cells. The cutoff for the MTT Assay may have
been a bit too conservative, as it eliminated only one additional compound
(Wortmannin) from the study. The majority of the drugs used, however,
including those that would prove most effective at blocking VZV replication, did
not inhibit cell proliferation at the highest concentrations tested.
Assessment of the antiviral capacity of the remaining compounds
distinguished the ten most effective inhibitors of VZV replication. Potency of
compounds that were not eliminated by the Neutral Red or MTT Assays was first
assessed by the Dose Response Assay, where a cutoff of twenty-percent viral
yield at 12 µM was used to keep only the most efficacious inhibitors in the study
for further analysis. The 12 µM cutoff was selected for its proximity to the

34
attainable in vivo concentration of 10 µM and the Neutral Red cutoff used earlier.
Application of these criteria narrowed the list of compounds to the sixteen most
effective drugs and ten compounds remained after EC50 concentrations and SI
values were calculated. An SI value of 10 is the industry standard used in
evaluating the potential of a compound for use in vivo and thus served as the
cutoff in our study. The limits used in selecting this final group of compounds
proved to be appropriate: it is unlikely that any highly effective drugs were
eliminated too early. The rejected compounds simply lacked potency.
The compounds highlighted by this study affect targets that are critical
mediators of the viral lifecycle. Identification of these targets as well as
knowledge of their function has led to the development of a working model
detailing their relationships and roles in VZV replication (Fig. 9). Of the ten
most promising drugs identified in this study, three (Tyrphostin AG1478,
Tyrphostin 9, and AG-879) are selective inhibitors of growth factor receptor
tyrosine kinases (GFRTKs). This is a particularly exciting finding as the
independent action of three inhibitors confirms the importance of these proteins
as antiviral targets. GFRTKs are subdivided into epidermal growth factor
receptor kinases (EGFRK), platelet-derived growth factor receptor kinases
(PDGFRK), and neuronal growth factor receptor kinases (NGFRK) that are
expressed in the fibroblasts used in these experiments and many other cell types.
GFRTKs are important membrane-bound signal transducing proteins that initiate
cell-signaling cascades that activate, among others, the Ras, MAPK, PI3K, Akt,
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and JAK pathways. These pathways elicit a variety of responses that promote
cell growth, proliferation, differentiation, survival, transcription factor
production, and gene expression (Alberts et al., p. 555-567). Given the multitude
of activities initiated by these enzymes, GFRTKs have become a common target
in the treatment of malignant and non-malignant disorders (Grimminger et al.,
2010). Activation of both EGFRK and PDGFRK signaling are required for
human cytomegalovirus (HCMV) infection, a member of the herpes virus family
(Evers et al., 2004; Soroceanu et al., 2008). Similarly, inhibition of GFRKs
prevented viral pathogenesis during herpes simplex virus 1 (HSV-1) infection in
mice (Sharma et al., 2011). Moreover, AG-879 and Tyrphostin 9 exhibit
antiviral activity against a wide variety of viruses including HSV-1 (Kumar et
al., 2011). It is no surprise then that the GFRTKs were implicated in this study
as logical targets for the replication of VZV. It is possible that VZV interacts
with these receptor kinases before or upon entry into the host cell to activate
mechanisms necessary for expression of viral proteins.
Two of the final ten drugs are Protein Kinase C (PKC) inhibitors (PKC412, GF 109203X). Like the GFRTKs, the implication of two separate drugs as
high quality treatments validates the essential role of PKC in VZV replication.
The importance of PKC in modulating the VZV life cycle was confirmed by
Bontems et al. (2002) when they demonstrated that PKC phosphorylates the
VZV protein IE63, which is a key regulator of viral gene expression previously
shown to be essential for virus replication by Sommer et al. (2001). PKC is a
central protein that is activated by a number of receptor signaling pathways,
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including those initiated by the GFRTKs, which modulates a vast array of
cellular processes. PKC functions vary by cell type, but common responses
include cell growth, transcription regulation, and alteration of membrane
structure (Newton, 1995). The activity of a multifunctional effector like PKC, in
addition to its known interaction with viral proteins, makes it an important
cellular target of VZV.
Two glycogen synthase kinase 3β (GSK-3β) inhibitors (Kenpaullone and
Indirubin-3’-monooxime) were also potent antiviral compounds in the study.
Like PKC, GSK-3β is another diverse signaling protein that regulates a variety of
cellular functions. Most notably, GSK-3β is involved in metabolism, gene
expression, neuronal development, and regulation of cell death by facilitating
apoptotic pathways (Grimes & Jope, 2001). GSK-3β activity is regulated by
epidermal growth factor (EGF) and the EGFRK pathway (Saito et al., 1994).
The nature of this regulation appears to be inhibitory, however, so its role in
preventing VZV replication is unclear. Furthermore, GSK-3β is involved in both
stimulatory and inhibitory crosstalk with a number of other signaling proteins
like Protein Kinases A, B (Akt), and C (Grimes & Jope, 2001), making its role in
VZV infection difficult to discern.
A Ca2+/Calmodulin-dependent protein kinase II (CaMKII) inhibitor, KN62, was also found to have antiviral activity by this analysis. CaMKII requires
activation by calcium ions. The relationship between VZV and intracellular
calcium is poorly understood, but other viruses in the herpesviridae family are
known to transiently increase the concentration of Ca2+ ions to induce calcium-
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signaling pathways (Cheshenko et al., 2003). CaMKII is another signaling hub
that phosphorylates many downstream effector proteins and is thusly an
important mediator in a number of pathways. CaMKII is expressed in all
eukaryotic cells (Alberts et al., 2010. p. 553) and, given its role in many signal
transduction pathways, would be a logical target for VZV to hijack.
Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, was also a drug
of significant importance in our analysis. Roscovitine has previously been
shown to disrupt VZV replication (S. Taylor et al., 2004), further validating the
findings of this study. Moreover, Leisenfelder et al. (2008) showed that a CDK
protein co-localized with and phosphorylated a VZV tegument protein in HFFs,
providing evidence of a direct interaction between VZV and host CDKs. CDKs
regulate cell cycle progression and are targeted by herpes viruses to promote
transcription and passage through the G1 phase of the cell cycle to the S phase
where viral DNA is replicated (Hardwick, 2000). This process is so important to
viral replication, in fact, that many herpes viruses encode their own cyclin
proteins to promote it (Mittnacht & Boshoff, 2000). It is not surprising then that
inhibition of these effectors resulted in prevention of VZV replication.
One final drug implicated by the panel analysis was H89  2HCl, an
inhibitor of Protein Kinase A (PKA), which is homologous to PKC and is an
important mediator in the activation of cellular transcription factors, which are
required for VZV mRNA synthesis (Rahaus & Wolff, 2003). A role of PKA in
VZV infection was shown by Desloges et al. (2008) when they demonstrated that
substrates of PKA are phosphorylated during VZV infection and that treatment
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with an inhibitor of PKA dramatically reduced virus replication in fibroblasts.
The effects of PKA activity vary depending on cell type, but it is certainly a
crucial target for VZV.
Together, the results of this project have implicated specific host kinases
as essential for VZV replication. Although the identification of these proteins is
an important first step in the development of antiviral medication, a number of
additional assays would provide critical evidence of the roles and effectiveness of
kinase inhibitors as therapy for varicella and zoster. Five potential laboratory
studies will be discussed here.
The first logical future study we would perform is the plaque assay, a
more standard virology technique used to detect virus concentration in a sample.
Plaque assays measure infectious particles such as virions, infected cells, or
syncytia in a sample. These particles form countable plaques (cleared areas) on a
monolayer of confluent cells. Each plaque represents an infectious particle
present in the original sample. Such an assay could be performed with the top
ten drugs identified in this study to validate our results.
Second, we would analyze the activation or inhibition of the cellular
proteins we identified as antiviral targets. Cell kinases are typically regulated by
phosphorylation on specific sites that can be detected by immunoblotting
(Western blot) techniques (Rahaus et al., 2005). To determine the effect of VZV
on the identified proteins, the concentration of their phosphorylated forms would
be compared in infected and uninfected cells as well as in the presence of their
inhibitors.
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Third, time of addition studies would be performed to help us further
understand the antiviral mechanisms of potent compounds. Witvrouw et al.
(1998) used this type of experiment to elucidate the mechanism of a drug that
inhibits the replication of VZV and other viruses. In this assay, drugs are added
to virus-infected cells at various times before and after infection. Virus
replication is later quantified and the results may point to the phase of the virus
lifecycle that is blocked by the compound. Some of the drugs identified in our
study may have much lower EC50 values before, during, or after infection
depending on the phase of infection they inhibit. Such a change in the EC50
concentration could make a compound even more effective than suggested by
this study if administered under the right conditions. The results of treatment
with GFRTK inhibitors would be of considerable interest in such an experiment
because it is possible that prophylactic administration of these compounds could
prevent virally mediated host-signaling and virus replication altogether. This
would be important in the treatment of immunocompromised individuals who are
at high risk for zoster. Results of time of addition studies would have a direct
implication on how therapeutic compounds targeting these proteins would be
used in a clinical setting.
Fourth, we would perform combination assays that could yield valuable
information regarding synergistic or antagonistic interactions between the kinase
inhibitors we identified and current antiviral medications. Such approaches have
been used to demonstrate the additive antiviral effects of antiherpes drugs and
interferon in treating VZV and HSV-1 (Baba et al., 1984; J. Taylor et al., 1998).

41
Combination therapy is common for many malignant and non-malignant diseases
and is used most notably in the treatment of HIV and hepatitis C. In this case,
the use of multiple kinase inhibitors may synergistically shut down a number of
crucial pathways and have greater antiviral activity than the independent effect of
each drug alone. Alternatively, because some of the targets identified in this
study regulate the activity of others, it is possible that co-inhibition may cancel
the effects of the individual inhibitors. These drugs can also be combined with
current medications to block viral replication by two separate mechanisms, which
could further suppress the development of drug resistance.
Finally, compounds that showed promise in cultured cells could be tested
in vivo in a severe combined immunodeficient (SCID) mouse model. The SCID
model is commonly used in the assessment of VZV pathogenesis (Arvin, 2006;
Ku et al., 2005; Zerboni et al., 2010). In these assays, SCID mice are implanted
with human skin and then VZV is inoculated directly into the tissue. The mice
are treated with antiviral drugs and virus yield is measured by in vivo
bioluminescence (Rowe, et al, 2010). Because the immune systems of SCID
mice have been completely removed, any effect on viral replication is the result
of treatment. This process is important in identifying how these drugs fit into a
clinical setting and determining the proper route of administration (i.e., topically
or systemically). Information from these studies would shed light on the
processing of drugs in an in vivo tissue environment. This is a crucial step in
assessing the potency and safety of drugs in a living system and serves as the
bridge from bench to bedside.
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Together, the results of this study have highlighted several important
cellular targets of VZV and expanded our understanding of host-virus
interactions that have the potential to lead to new treatments of VZV infection.
Although the findings of this project provide further evidence of the merits of the
host-centered paradigm, the medical community as a whole has thus far been
resistant to accept this chemotherapeutic approach to treating varicella and
zoster. We hope that the results of this project will strengthen the perception of
these methods in combating these diseases and lead to continued efforts in the
development of host-targeted antivirals.
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